Klotho Neurosciences Inc. (KLTO)
NASDAQ: KLTO
· Real-Time Price · USD
1.52
-0.49 (-24.38%)
At close: Jun 11, 2025, 3:59 PM
1.72
12.83%
Pre-market: Jun 12, 2025, 08:07 AM EDT
Company Description
Klotho Neurosciences, Inc., a biopharmaceutical company, develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders.
Its lead gene therapy product candidates include AMI-101 for the treatment or prevention of Alzheimer's disease; and AMI-202 to treat and prevent amyotrophic lateral sclerosis.
The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024.
The company is based in Omaha, Nebraska.
Klotho Neurosciences Inc.
| Country | United States |
| IPO Date | n/a |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Dr. Joseph Sinkule Pharm.D. |
Contact Details
Address: 13576 Walnut Street Omaha, Nebraska United States | |
| Website | https://klothoneuro.com |
Stock Details
| Ticker Symbol | KLTO |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | n/a |
| CUSIP Number | n/a |
| ISIN Number | US49876K1034 |
| Employer ID | - |
| SIC Code | n/a |
Key Executives
| Name | Position |
|---|---|
| Dr. Joseph Sinkule Pharm.D. | Founder, Chief Executive Officer, Chairman of the Board & Secretary |
| Jeffrey LeBlanc | Chief Financial Officer |
| Dr. Bradford A. Navia M.D., Ph.D. | Chief Medical Advisor |
| Dr. Miguel Chillon Rodriguez | Chief Scientific Advisor & Consultant |